Mersana Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Mersana Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financial-reporting
TL;DR
**Mersana Therapeutics Q1 2025 10-Q filed. Financials and operations update.**
AI Summary
Mersana Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment information are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and stakeholders with an update on Mersana Therapeutics' financial health and operational progress during the first quarter of 2025, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Mersana Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Mersana Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report for the 10-Q
- 20250515 (date) — Filing date of the 10-Q
- 840 Memorial Drive, Cambridge, MA 02139 (address) — Business and mailing address of Mersana Therapeutics
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
The filing date (FILED AS OF DATE) is 20250515.
What is Mersana Therapeutics' primary industry classification?
Mersana Therapeutics is classified under Pharmaceutical Preparations [2834].
What is the company's state of incorporation?
Mersana Therapeutics, Inc. is incorporated in Delaware (DE).
What is the SEC file number for Mersana Therapeutics?
The SEC File Number is 001-38129.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Mersana Therapeutics, Inc..